|

177Lu-BetaBart Clinical Trials

1 actively recruiting trial across 1 location

Also known as: B335 177Lu-DOTA-anti-B7-H3, RV-01

Pipeline

Phase 1/2: 1

Top Sponsors

  • Radiopharm Theranostics, Ltd1

Indications

  • Head &Amp; Neck Squamous Cell Carcinoma (HNSCC)1
  • Castration-Resistant Prostate Cancer (CRPC)1
  • TNBC - Triple-Negative Breast Cancer1
  • Small Cell Lung Cancer (SCLC)1
  • NSCLC (Non-small Cell Lung Cancer)1

Dothan, Alabama1 trial

177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors

Dothan Hematology & Oncology

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.